

25 February 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Wednesday 12 February 2025. I am pleased to confirm the following.

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- **Avelumab + Axitinib**
- **Axinitib**
- **Cabozantinib**
- **Everolimus**
- **Lenvatinib + Everolimus**
- **Lenvatinib + Pembrolizumab**
- **Nivolumab monotherapy**
- **Nivolumab + Cabozantinib**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab monotherapy**
- **Pembrolizumab + Axitinib**
- **Radiotherapy only**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

0 Patients

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- **Avelumab + Axitinib (Bavencio + Inlyta)**
- **Cabozantinib (Cometriq)**
- **Nivolumab (Opdivo)**
- **Nivolumab + Cabozantinib (Opdivo + Cometriq)**
- **Nivolumab + Ipilimumab (Opdivo + Yervoy)**
- **Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda)**

0 Patients

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- **Nivolumab (monotherapy)**
- **Nivolumab + Ipilimumab**
- **Nivolumab + Cabozantinib**
- **Avelumab + Axitinib**
- **Lenvatinib + Pembrolizumab + (Kispalyx + Keytruda)**

0 Patients

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Please see attachment.

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Information Governance Administrator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.